Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Anti-vimentin nanobody decreases glioblastoma cell invasion in vitro and in vivo
ID
Zottel, Alja
(
Author
),
ID
Novak, Metka
(
Author
),
ID
Šamec, Neja
(
Author
),
ID
Majc, Bernarda
(
Author
),
ID
Colja, Sara
(
Author
),
ID
Katrašnik, Mojca
(
Author
),
ID
Vittori, Miloš
(
Author
),
ID
Hrastar, Barbara
(
Author
),
ID
Rotter, Ana
(
Author
),
ID
Porčnik, Andrej
(
Author
),
ID
Lah Turnšek, Tamara
(
Author
),
ID
Komel, Radovan
(
Author
),
ID
Breznik, Barbara
(
Author
),
ID
Jovchevska, Ivana
(
Author
)
PDF - Presentation file,
Download
(2,42 MB)
MD5: 20A08AEB81A7FB4472C0B7E6E26554AB
URL - Source URL, Visit
https://www.mdpi.com/2072-6694/15/3/573
Image galllery
Abstract
Purpose: Glioblastoma (GBM) is the most common primary brain tumour and one of the deadliest cancers. In addition to late diagnosis and inadequate treatment, the extremely low survival rate is also due to the lack of appropriate therapeutic biomarkers and corresponding therapeutic agents. One of the potential therapeutic biomarkers is the intermediate filament vimentin, which is associated with epithelial-mesenchymal transition (EMT). The purpose of this study was to analyse the effect of the anti-vimentin nanobody Nb79 on cell invasion in vitro and in vivo. To further our understanding of the mechanism of action, we investigated the association between Nb79 and EMT in GBM and GBM stem cells by analysing the expression levels of key EMT-related proteins. Methods: The expression of vimentin in glioma tissues and cells was determined by RT-qPCR. An invasion assay was performed on differentiated glioblastoma cell line U-87 MG and stem cell line NCH421k in vitro as well as in vivo in zebrafish embryos. The effect of Nb79 on expression of EMT biomarkers beta-catenin, vimentin, ZEB-1 and ZO1 was determined by Western blot and immunocytochemistry. Results: Our study shows that vimentin is upregulated in glioblastoma tissue compared to lower grade glioma and non-tumour brain tissue. We demonstrated that treatment with Nb79 reduced glioblastoma cell invasion by up to 64% in vitro and up to 21% in vivo. In addition, we found that the tight junction protein ZO-1 had higher expression on the cell membrane, when treated with inhibitory anti-vimentin Nb79 compared to control. Conclusion: In conclusion, our results suggest that anti-vimentin nanobody Nb79 is a promising tool to target glioblastoma cell invasion.
Language:
English
Keywords:
glioblastoma
,
vimentin
,
nanobody
,
invasion
,
EMT
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
BF - Biotechnical Faculty
FKKT - Faculty of Chemistry and Chemical Technology
Publication status:
Published
Publication version:
Version of Record
Year:
2023
Number of pages:
14 str.
Numbering:
Vol. 15, iss. 3, art. 573
PID:
20.500.12556/RUL-154097
UDC:
616-006
ISSN on article:
2072-6694
DOI:
10.3390/cancers15030573
COBISS.SI-ID:
138228995
Publication date in RUL:
25.01.2024
Views:
584
Downloads:
79
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Cancers
Shortened title:
Cancers
Publisher:
MDPI
ISSN:
2072-6694
COBISS.SI-ID:
517914137
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
glioblastom
,
vimentin
,
nanotelo
Projects
Funder:
ARRS - Slovenian Research Agency
Funding programme:
Young researchers
Funder:
ARRS - Slovenian Research Agency
Project number:
Z3-2649
Name:
Določitev novih biomarkerjev glioblastoma za namen neinvazivne tekočinske biopsije
Funder:
ARRS - Slovenian Research Agency
Project number:
Z3-4510
Name:
Vpliv imunoterapije z anti-PD-L1 atezolizumabom in nanotelesom Nb202 na organoide glioblastoma, pripravljene iz tkiva bolnikov
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0390
Name:
Funkcijska genomika in biotehnologija za zdravje
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0245
Name:
Ekotoksiologija, toksikološka genomika in karcinogeneza
Funder:
ARRS - Slovenian Research Agency
Project number:
P4-0432
Name:
Morska in mikrobna biotehnologija
Funder:
EC - European Commission
Funding programme:
Interreg V-A It.-Slo.
Project number:
146
Acronym:
TRANS-GLIOMA
Funder:
EC - European Commission
Funding programme:
HE
Project number:
101079113
Name:
Twinning for excellence to strategically advance research in carcinogenesis and cancer
Acronym:
CutCancer
Funder:
ARRS - Slovenian Research Agency
Project number:
J3-4504
Name:
Z vizualizacijo mikrookolja glioblastoma do boljše terapije
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back